Caspofungin Contraindications and Precautions
Concomitant Use and Dose Adjustments
- The American College of Clinical Pharmacology recommends using caspofungin with cyclosporine only when the potential benefit outweighs the risk, as cyclosporine increases caspofungin area under the curve by approximately 35% 1, 2
- Inducers of drug clearance, such as efavirenz, nelfinavir, nevirapine, phenytoin, rifampin, dexamethasone, and carbamazepine, may reduce caspofungin concentrations, requiring a dose increase to 70 mg daily 1, 2
- Caspofungin reduces tacrolimus area under the curve by approximately 20%, requiring monitoring of tacrolimus levels and dose adjustment accordingly 1, 2
Hepatic Impairment and Dose Reduction
- The Infectious Diseases Society of America recommends a dose reduction for moderate hepatic insufficiency (Child-Pugh score 7-9), reducing the daily maintenance dose to 35 mg 3
- Caspofungin undergoes hepatic metabolism with some spontaneous chemical degradation, requiring monitoring of patients with abnormal liver function tests for evidence of worsening hepatic function 1, 3
Renal Insufficiency and Dose Adjustment
- No dosage adjustment is required for renal insufficiency or dialysis, according to the Clinical Pharmacology guidelines 3
Caspofungin Dosing in Patients with Hepatic Impairment
Monitoring and Dose Adjustment
- The Infectious Diseases Society of America recommends monitoring liver enzymes closely in all patients with hepatic impairment receiving caspofungin, as Grade IV liver enzyme elevations occurred in 27.7% of liver transplant recipients 4, 5, 6, 7
- In liver transplant patients receiving caspofungin prophylaxis, standard dosing is 70 mg loading dose followed by 50 mg daily, with a duration of 21 days in the pivotal trial 4, 5, 6, 7
Special Population Considerations
- The American Society of Transplantation suggests that concomitant use of caspofungin with cyclosporine or tacrolimus is generally safe without additional hepatotoxicity, though close monitoring is warranted 4, 5, 6, 7